April 17, 2024
With programs specifically developed for Oracle’s regional customer communities, this multifaceted event provides compelling sessions led by Oracle customers and industry thought leaders.
Meet with your peers and gain perspective on industry trends from leading experts on artificial intelligence, cloud-based research, real-world evidence, innovative study-site selection/activation/analytics, and additional advances that are transforming and streamlining clinical and safety development.
Chicago Theme: See data in new ways, discover insights, and unlock endless possibilities
The last few years have been marked by a rapid period of technological adoption in the life sciences industry, mostly driven by the pandemic. Now as the industry moves ahead, it is committed to finding new ways to apply technology to improve clinical research, expand trials to wider, more diverse population sets, and improve drug safety. Clinical research, combined with real-world data (RWD), provides deeper insights into the natural history of diseases and the performance of healthcare interventions in real-world settings. These real-world data sources, which can include patient-reported outcomes, insurance claims data, data from wearable devices, and detailed patient histories found in electronic health records (EHRs) can provide a more refined understanding of treatments in real-life settings. This data will become pivotal in enhancing clinical trial execution, generating drug safety and efficacy evidence, and supporting drug reimbursement strategies.
Dr. Christopher Boone, Group Vice President Research Services of HSGIU (Oracle Life Sciences), will be presenting the opening address at the Oracle Life Sciences Connect Chicago 2024 event at the Oracle Innovation Lab. He will be highlighting the necessity of Real World Data (RWD) and Real World Evidence (RWE) to advance the life sciences industry, and how Oracle is uniquely positioned to serve unmet needs in clinical research. Dr. Boone will articulate the value of the combination of Oracle and Cerner, and the tremendous impact of using RWD to evaluate the effectiveness of potential drugs, vaccines, and medical devices.
Group Vice President Research Services, Oracle
Inefficiencies in patient recruitment continue to be a prevalent challenge in clinical research and significantly impact all stakeholders of the life sciences industry. Approximately $1.9 billion is spent on recruitment annually and 48% of research sites enroll one or fewer patients for a given trial. Oftentimes, 72% of trial participants are already patients at the site and 28% are new patients. Strong site relationships, deep clinical research expertise, and robust technology is key to achieving better study feasibility and high confidence in the eligibility of enrolled participants. Learn about how Oracle supports research readiness with end-to-end tooling for site selection, study feasibility, and patient recruitment which is powered by EMR data.
Principal Innovation Architect, Oracle Life Sciences
Senior Director, Learning Health Network, Oracle Life Sciences
Senior Director of Product Management, Oracle Life Sciences
Oracle is excited and honored to participate in the Cancer Moonshot’s new CancerX public-private partnership. In response to the White House Cancer Moonshot, the Digital Medicine Society (DiMe) and Moffitt Cancer Center currently co-host CancerX, an initiative to rapidly accelerate the pace of cancer innovation in the U.S., alongside the Office of the National Coordinator for Health Information Technology (ONC), and the Office of the Assistant Secretary for Health (OASH). CancerX’s inaugural project focuses on using digital innovation to reduce disparities and financial toxicity in cancer care and research. CancerX uses a three-pronged approach to generate impact in cancer research and care: conducting pre-competitive evidence generation; establishing an accelerator cohort; and leading demonstration projects. The CancerX project team will establish best practices, build capacity, and demonstrate the impact of innovation on the life of every person on a cancer journey.
Founder of Enlightening Results and co-Founder, Unblock Health
Associate Center Director, Moffitt Cancer Center
The convergence of science and emerging technologies, such as AI and machine learning, is enabling patient-centric approaches to clinical trials with data-driven insights to optimize study design, predict patient responses, improve patient adherence and retention, and to foster inclusiveness and diversity. Capturing the patient voice through the collection of real-world data (eg. EHRs, claims, disease registries, digital health apps, social media) is an integral part of this approach and critical for efficient post-marketing studies. AI-enabled applications and algorithms are also impacting the full lifecycle of therapeutic development, from discovery to commercialization, with the power to find patterns lost by conventional data analysis. Learn how Oracle is helping life science organizations unify data and analytics across the enterprise to unlock the full potential of their mission critical data through our Life Sciences applications, Oracle Cloud Infrastructure, and data & analytics services.
Industry Cloud Strategy Specialist, Oracle
In recent years, we have seen many new companies appear on the tech-enabled clinical trials and DCT ‘scene’, claiming to have solutions that solve ALL the problems and make ALL the pain points a thing of the past with new and innovative approaches to their tech product development. Some legacy players have made significant acquisitions to solve the problem, but have struggled with the integration between their existing and these next gen systems, and so still operate as separate siloed parts within the ‘whole’. We must ask ourselves, when you try to be everything, can you be anything, and have we really reduced burden from the clinical continuum? Has our focus on technology only compounded the problems that a tech forward play overlooks the key role that services and consulting play in a clinical trial. The ObvioHealth and Oracle partnership is a representation of ‘unlocking the best value where it resides’. Oracle has the deep tech expertise in data consolidation and site data capture facing aspects of clinical trial data entry, and ObvioHealth has prioritized the participant experience. Both taking a considered approach to tech development and focusing on what you can do, and doing it well. Both teams emphasize the subject matter expertise that their services teams bring to engagements. This panel will discuss the wider issue of a single company trying to be everything and not effectively meeting expectations, and if this should still be the goal, or if partnerships that tie technology, process and insights with interoperability and automation should be the focus. Discussion will then turn to a use case of the ObvioHealth-Oracle partnership, including lessons learned both operationally and scientifically.
Implementation Project Manager, ObvioHealth
Sr. Principal Design Consultant, Oracle
Explore the future of pharmacovigilance including challenges and opportunities faced by safety professionals, and advances in technology that can help address these needs. Join us and our global community of customer advocates and industry leaders at the for in-depth discussions about overcoming challenges specific to gaining insights to stay ahead in this ever-evolving field & ensure optimal patient safety.
Global Head and Strategic Advisor, MultiVigilance, Oracle
Join industry peers in a Q&A session on hot topics in PV, including the future of precision pharmacovigilance—leveraging RWE/ RWD assets in revolutionary ways, customer perspectives on automation and AI in safety and signal detection, and innovating for the future with Oracle.
VP Safety & Pharmacovigilance, Oracle
VP Product Management, Oracle
It has been a long-standing industry problem that 50-70% of data collected in EDC is being manually re-entered from EHR systems by Site staff who would rather spend their time on patient care and patient safety. As a result of duplicate data entry, nearly 20-25% of study costs are related to manual transcription, using three minutes per data point (on data entry, validation, correction) and there is an average lost earning per day of $8 million. Oracle aims to address this problem with the acquisition of Cerner and transform the way healthcare data is transferred to clinical trial systems for Clinical research. Our goal is to extract healthcare data from EHR systems in a way so that it can be the bloodline for accelerating clinical trials.
Vice President, Oracle Clinical Trials
Envision a future where seamless collaboration across the multiomics continuum propels us beyond current boundaries, bridges gaps in research, and creates unprecedented clinical advancements. This transformative collaboration will revolutionize disease prevention and treatment. Join us on a journey through the current genomics landscape, delving into challenges faced by healthcare organizations, patients, and researchers. We will explore the intersection of clinical and research workflows providing a comprehensive understanding of key intersection points. Learn from experts like Terah Collins, Senior Director of Multiomics Products at Oracle about the impact of emerging technologies, from single-cell sequencing to AI driven analytics and how the Oracle Innovation Network aligns individual goals of each segment, driving progress towards unified, improved health.
Senior Director, Multiomic Products
Oracle Cloud Infrastructure and Innovative Solutions enhance and accelerate the clinical development process and timeline of a drug. These provide pharma commercial teams with more robust and rich clinical data sets more efficiently and quickly, while also increasing the urgency of developing a commercialization strategy to make the drug available to and improve the lives of patients in need. Jay Grisolano, PhD, will highlight how Oracle Life Sciences supports our commercial clients with Oracle Real World Data and custom consulting solutions to inform their strategy ensuring successful launch and marketing of their drug, as well as monitoring post-launch performance and perception.
Principal, Oncology and Specialty Therapeutics, Oracle
Vice President Sales, Oracle
End the day by joining Oracle for a fun filled networking reception with cocktails, conversations, and canapés! Plus join one of our Innovation Lab tours to learn about Oracle’s most cutting-edge technologies.
Today, clinical trial teams and sites rely on a collection of siloed point solutions and disparate data sources, creating redundancy and inefficiency. What if you could build a study once, enter data once, and do everything in one place?
Explore Oracle Life Sciences solutions and resources.